{"id":2525,"date":"2026-04-20T11:37:20","date_gmt":"2026-04-20T11:37:20","guid":{"rendered":"https:\/\/emergencydrug.com\/?post_type=product&p=2525"},"modified":"2026-04-21T06:14:42","modified_gmt":"2026-04-21T06:14:42","slug":"tucaxen-150-mg-tucatinib","status":"publish","type":"product","link":"https:\/\/emergencydrug.com\/ar\/shop\/tucaxen-150-mg-tucatinib\/","title":{"rendered":"Tucaxen 150 MG (Tucatinib) – 30 Tablets"},"content":{"rendered":"

Product Features of\u00a0 Tucaxen 150 mg:<\/em><\/strong><\/h4>\n\n\n\n\n\n\n\n\n\n\n\n
Product Name<\/td>\n: Tucaxen<\/span><\/td>\n<\/tr>\n
Generic Name<\/td>\n: Tucatinib<\/span><\/td>\n<\/tr>\n
Manufacturer<\/td>\n: Everest Pharma Ltd<\/td>\n<\/tr>\n
Indication<\/td>\n: Breast Cancer<\/td>\n<\/tr>\n
Formulation<\/td>\n: Tablet<\/td>\n<\/tr>\n
Strength<\/td>\n: 150 mg<\/td>\n<\/tr>\n
Quantity<\/td>\n: 30 Tablets<\/td>\n<\/tr>\n
Storage<\/td>\n: Below 30\u00b0<\/td>\n<\/tr>\n
Registrations<\/td>\n: Export Only<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Tucaxen 150 mg price:<\/strong> $550.00<\/p>\n

 <\/p>\n

Tucaxen 150 Mg (Tucatinib), generic Tukysa, is used with trastuzumab (Herceptin) and capecitabine (Xeloda) to treat a certain type of hormone receptor-positive breast cancer that has spread to other parts of the body and cannot be treated with surgery in adults who have already been treated with at least one other chemotherapy medication. Tucatinib is in a class of drugs called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells.<\/span><\/p>\n

 <\/p>\n

Composition<\/span><\/strong><\/h2>\n

Tucaxen 50 Tablets<\/span><\/strong>: Each film-coated tablet contains Tucatinib INN 50 mg.\u00a0<\/span><\/p>\n

Tucaxen 150 Tablets<\/span><\/strong>: Each film-coated tablet contains Tucatinib INN 150 mg.\u00a0<\/span><\/p>\n

 <\/p>\n

Pharmacology\u00a0<\/span><\/strong><\/h3>\n

\u00a0Mechanism of Action of\u00a0 Tucaxen 150 mg <\/span><\/strong><\/p>\n

Tucatinib<\/a> is a tyrosine kinase inhibitor of HER2. In vitro, it inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed anti-tumor activity in HER2 expressing tumor cells. In vivo, it inhibited the growth of HER2 expressing tumors. The combination of Tucatinib and trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either drug alone.\u00a0<\/span><\/p>\n

 <\/p>\n

Pharmacodynamics<\/span><\/strong><\/p>\n

\u00a0Exposure Response Relationship:\u00a0<\/span><\/strong>Tucatinib exposure-response relationships and the time course of pharmacodynamics response have not been fully characterized.\u00a0<\/span><\/p>\n

Cardiac Electrophysiology:<\/span><\/strong> No large mean increase in QTc (i.e., > 20 ms) was detected following treatment at the recommended dose of 300 mg taken orally twice daily.<\/p>\n

Pharmacokinetics:<\/span><\/strong> Tucatinib AUCO-INF and Cmax increase proportionally over a dosage range from 50 mg to 300 mg (0.17 to 1 times the approved recommended dosage). Tucatinib exhibited 1.7-fold accumulation for AUC and 1.5-fold accumulation for Cmax after administering Tucatinib 300 mg twice daily for 14 days. The time to steady state was approximately 4 days.<\/p>\n

Absorption:\u00a0<\/span><\/strong>The median time to peak plasma concentration of Tucatinib was approximately 2 hours (range 1 to 4 hours).\u00a0<\/span><\/p>\n

Effects of Food:<\/span><\/strong><\/p>\n